To evaluate the perioperative antinociceptive effect of intrathecal morphine (a pure μ agonist), intravenous (IV) buprenorphine (a partial μ agonist) or their combination.
Buprenorphine, a partial μ-receptor agonist, is approved for the management of moderate to severe pain, but it has low oral bioavailability.
It has also been shown to produce analgesic effects, most probably acting as a partial agonist at the μ-opioid receptor.
The intersection is built as a partial cloverleaf interchange.
TC serves as a partial agonist of this receptor.
The drug is categorized as a "partial opiate agonist".
As a rule μ 1 and μ 2 are positive decimal fractions.
Buprenorphine, a partial agonist of the μ-opioid receptor, binds with weak morphine-like activity and is used clinically as an analgesic in pain management and as an alternative to methadone in the treatment of opioid dependence.
In a study by Kouri et al. [ 14] opiate addicts were detoxified and then treated with and without buprenorphine, a partial κ-antagonist and μ-agonist.
Taking μ as the mean level of the molecules of interest and μ X 1 as the mean level in the monomeric model, the ratio μ μ X 1 - 1 is plotted as a function of μ X 1 in Figure 1.
